Viking Therapeutics Inc Stock

Shares in Viking Therapeutics (NASDAQ: VKTX) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its

As of Aug. 20, shares of Viking Therapeutics (NASDAQ: VKTX) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its

Shares of Viking Therapeutics (NASDAQ: VKTX) rose by almost 10% at 11 a.m. ET today. This follows a significant fall the previous day on the release of its eagerly awaited top-line results from a

Viking Therapeutics (NASDAQ: VKTX) stock collapsed in morning trading Tuesday, down more than 40% after reporting mixed results for its GLP-1 weight loss pill VK2735. As Viking shares plummet

Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss

Viking Holdings(NYSE:VIK) reported second-quarter 2025 earnings on August 19, 2025, achieving 18.5% year-over-year revenue growth to $1.9 billion, an adjusted EBITDA increase of 28.5% to $633

Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week.

The clinical-stage biotech

Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.

That's

Investing successfully in biopharmaceutical companies can sometimes require complicated calculations worthy of Albert Einstein's brain. That's because picking the right ones involves a variation of

Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and

Norwegian Cruise Line Holdings (NYSE: NCLH) benefited from a significant bump following earnings, rising 9% in the following trading session. With record revenue and strength in all three of its

While most investors pile into Eli Lilly (NYSE: LLY) or flee from struggling Novo Nordisk (NYSE: NVO), they're missing a compelling opportunity in the clinical-stage space. Novo recently lost nearly

Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than

Explore the exciting world of Viking Therapeutics (NASDAQ: VKTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on treatments for obesity and metabolic diseases, released results for its second quarter on July 23, 2025. The

Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged

Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.

Three

Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged